ArticleCureus2025
Granulocyte Colony-Stimulating-Factor-Producing Bladder Carcinoma: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Granulocyte colony-stimulating factor (G-CSF)-producing bladder carcinoma has an aggressive clinical course. We report a case of G-CSF-producing bladder carcinoma in a 78-year-old Japanese man who had a bladder tumor with a diameter of 38 mm. Transurethral resection of the bladder tumor was performed. Pathological examination revealed a high-grade muscle-invasive urothelial carcinoma (pT2). The patient had three courses of neoadjuvant chemotherapy with a combination of gemcitabine and carboplatin and thereafter underwent robot-assisted radical cystectomy. The surgically resected bladder specimen contained a highly invasive tumor with necrosis. The tumor cells showed marked cytological atypia with brisk mitosis. The tumor had metastasized to a regional lymph node. Therefore, we pathologically diagnosed high-grade invasive urothelial carcinoma, stage pT3b pN1. Thirty-six days after radical cystectomy, computed tomography revealed local recurrence and para-aortic and bilateral common iliac lymph node metastasis (white blood cell count had increased to 46,970/µL). Fifty-seven days after radical cystectomy, the white blood cell count further increased to 83,700/µL, and the serum G-CSF level was 186 pg/mL (normal range, 10.5-57.5 pg/mL). G-CSF immunohistochemistry was performed, and diffuse cytoplasmic positivity for G-CSF was verified. Therefore, we considered that a leukemoid reaction had occurred because of G-CSF-producing bladder carcinoma. Seventy-seven days after radical cystectomy, the patient died because of the recurrence of bladder carcinoma (white blood cell count: 85,660/µL). If a clinician observes bladder carcinoma with an abnormal number of white blood cells despite the lack of a hematopoietic neoplasm or inflammation, G-CSF-producing bladder carcinoma should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.